AIDS Therapies

New Anti-HIV Drug Enters Clinical Trials

Published in AIDS Weekly, June 10th, 1996

At the same time its anti-HIV properties were announced, a new drug entered clinical trials in Europe.

The drug, 1,1'-azobisformamide or ADA, is an azoic compound with a molecular weight of 116.08 and the structural formula H₂ N-OC-N=N-CO-NH₂ .

M. Vandevelde of Hubriphar SPRL, Brussels, Belgium, and colleagues reported in a letter to the journal AIDS Research and Human Retroviruses that ADA dissolved in DMSO inhibited both HIV-1 and HIV-2 in cultures of human peripheral blood lymphocytes ("ADA, A Potential Anti-HIV Drug," AIDS Res H, 1996;12(7):567-8).

Vandevelde et al. then went on to announce that human...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry